SmiLe is pleased to announce a new sponsorship collaboration with Magle Chemoswed, a Malmö-based contract development and manufacturing organization (CDMO) that helps companies in the pharmaceutical and medical device industries take their innovations from idea to product.
With this new partnership, the SmiLe community will get access to Magle Chemoswed’s extensive expertise and experience in early development and GMP-compliant manufacture of complex APIs and finished drug and medical technology products.
As part of SmiLes’ strategy to provide a broad range of services to member companies, SmiLes’ industry sponsorship program is a strategic cornerstone in providing easy, on-site access to critical expertise.
“Magle Chemoswed is an excellent addition to the SmiLe sponsors and I look forward to our cooperation. The expertise that they bring to our community is very much in demand and I am convinced that this will have a positive impact on our companies,” says Ebba Fåhraeus, CEO of SmiLe.
As part of the sponsorship, Magle Chemoswed, will provide SmiLes’ incubator companies with critical advisory and development support in the transfering of new drug development projects from SmiLes lab facilities to scale-up GMP production of clinical and commercial batches.
“SmiLe has built over the years an impressive track record of successful startup incubations, helping research-intensive life science companies bring their innovations to life. At Magle Chemoswed we understand the risk and complexity around the development of a pharmaceutical candidate. As a one-stop shop with fully integrated services and a tested and proven right first time philosophy, we believe our knowledge and experiences can make a positive difference to SmiLe companies and look forward to starting our cooperation”, says Simon Jegou, Chief Strategy Officer, Magle Group.
Current SmiLe sponsors are Agilent, Sparbanken Skåne, Awa, Høiberg, Prevas, Setterwalls, Zacco, Magle Chemoswed, NanoTemper Technologies, Phase Holographic Imaging and ChemoMetec.
For more information: Ebba Fåhraeus, CEO of SmiLe, +46 73 400 04 33, email@example.com
About Magle Chemoswed: The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes two operational areas: Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products based on its proprietary and proven Degradable Starch Microsphere technology platform (DSM). Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com